GAIA-102 registry update: intraperitoneal study stays recruiting in advanced gastrointestinal cancer
A ClinicalTrials.gov registry observation shows GAIA-102 remains recruiting in PHASE1, PHASE2 for advanced gastrointestinal cancer with malignant ascites.
GAIA-102 is listed as RECRUITING in PHASE1 and PHASE2 for advanced gastrointestinal cancer of microsatellite stable with malignant ascites. The registry observation was published 2026-11-20T00:00:00+00:00, and the study has no posted results yet. For readers, the main takeaway is simple: this is an active study, not a finished one.
The trial is sponsored by Kyushu University and is organized as a RANDOMIZED study with separate phase I and phase II parts. Its structure includes a Phase I Monotherapy Cohort, a Phase I Combination Cohort, and phase II groups for gastric cancer and pancreatic cancer, alongside active comparator groups. That design suggests the study is comparing GAIA-102-based approaches with other listed regimens rather than testing a single path forward.
"Registry observation: GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (PHASE1, PHASE2, RECRUITING)" — ctgov_v2
What the study is testing
The listed interventions include GAIA-102 and Pembrolizumab, with Trifluridine/tipiracil hydrochloride (FTD/TPI) in one gastric cancer comparator group. In the pancreatic cancer part, the study lists GAIA-102 and Pembrolizumab added to standard therapy, while the comparator group uses standard therapy that includes Irinotecan hydrochloride hydrate, Calcium levofolinate hydrate, and Fluorouracil. Those names matter because they show the trial is comparing combination strategies against established treatment patterns already named in the registry.
The main phase I questions focus on safety. One outcome looks at the Number of participants of Dose Limiting Toxicity (DLT) with GAIA-102 during Cycle 1, which is defined as a 28-day cycle period. Another tracks the Frequency and severity of adverse events over 2 year, which means the early part of the study is watching closely for tolerance before any bigger conclusions are drawn.
"This record describes a study and its registry status; study outcomes require posted results." — ctgov_v2
Why the longer view matters
The phase II outcomes are centered on Overall survival in patients with gastric cancer up to 4 years and Overall survival in patients with pancreatic cancer up to 5 years, with up to 5.5 years for the Run-in Cohort. That tells readers the study is built to follow patients over a long stretch rather than deliver an immediate answer.
The primary_completion_date is 2032-03-31, and that date is marked ESTIMATED. So even though the study is active now, the timeline points to a long wait before any final readout could be expected from the registry alone. Until results are posted, the responsible reading is cautious: promising activity is not the same as proven benefit.